November 1st 2024
Clinicians discussed the complexities of diagnosing Long COVID, emphasizing the need for improved biomarkers and diagnostic technologies to better serve affected patients.
October 29th 2024
The CANOPY Phase 3 clinical trial demonstrated a reduced risk of symptomatic COVID-19, including a 64% reduction during the off-drug follow-up period.
October 29th 2024
Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.
October 24th 2024
Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.
October 11th 2024
A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Johnson & Johnson Report Promising COVID-19 Vaccine Booster Efficacy, Long-Term Data
September 21st 2021Preprint data from a real-world evidence assessment, as well as preliminary reports from a 2-dose trial, support the company's pursuit for FDA authorization of a second COVID-19 vaccine dose.
Read More
FDA Committee Votes to Recommend EUA of COVID-19 Booster Dose in Older, High-Risk People
September 17th 2021After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.
Read More
FDA Meeting Today to Discuss Booster Doses
September 17th 2021A Food and Drug Administration (FDA) committee will discuss this topic as it pertains to the potential approval of a third dose of the Pfizer-BioNTech COVID-19 vaccine. The results of this meeting could have ramifications for the Biden Administration’s COVID-19 health policy.
Read More
Maternity Mortality Increase During COVID-19 Affirms Value of Vaccination During Pregnancy
September 14th 2021A study from Mexico shows that maternal mortality increased nearly 60 percent during the COVID-19 pandemic, and reaffirms the importance of both COVID-19 and influenza vaccinations for pregnant women.
Watch
Review Panel: Scientific Evidence Does Not Support Booster Doses
September 13th 2021Even with the Delta variant as the predominant strain now, a group scientists concluded that vaccine efficacy against severe COVID-19 is so high that booster doses for the general population are not appropriate at this stage in the pandemic.
Read More
CDC: Vaccinated People Reduce Risk of COVID-19 Mortality by More Than 10 Times
September 10th 2021In a large study looking at incidence rates for hospitalization and mortality, results changed relatively little in terms of vaccine effectiveness, even after the Delta variant became the dominant strain.
Read More
2 Commerce Drive
Cranbury, NJ 08512